Hydroxychloroquine

Cross-source consensus on Hydroxychloroquine from 1 sources and 5 claims.

1 sources · 5 claims

Dosage & preparation

Hydroxychloroquine was given at 5 mg/kg per day throughout the two-year trial. — Abatacept versus hydroxychloroquine for prevention of rheumatoid arthritis in individuals with palindromic rheumatism: a randomized open-label trial
In the primary modified full analysis set, 18 of 36 hydroxychloroquine-treated participants developed rheumatoid arthritis during 24 months. — Abatacept versus hydroxychloroquine for prevention of rheumatoid arthritis in individuals with palindromic rheumatism: a randomized open-label trial
Hydroxychloroquine served as the active comparator in the PALABA trial. — Abatacept versus hydroxychloroquine for prevention of rheumatoid arthritis in individuals with palindromic rheumatism: a randomized open-label trial
Most hydroxychloroquine participants with available data were not diagnosed with rheumatoid arthritis during the two-year study period. — Abatacept versus hydroxychloroquine for prevention of rheumatoid arthritis in individuals with palindromic rheumatism: a randomized open-label trial
Hydroxychloroquine was considered a clinically relevant comparator despite reducing internal validity relative to placebo. — Abatacept versus hydroxychloroquine for prevention of rheumatoid arthritis in individuals with palindromic rheumatism: a randomized open-label trial